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Abstract
Background: This paper examines the degree of agreement among simple dichotomous self-report, validated screening
results, and biochemical screening results of prenatal alcohol and other drug use among pregnant women.
Method: Secondary analysis was conducted on a cohort of pregnant women 16 years or older, presenting for prenatal
care in the greater Cape Town, South Africa. Dichotomous verbal screening is a standard of care, and pregnant patients
reporting alcohol and other drug use in dichotomous verbal screenings were asked to engage in screening using the
Alcohol Smoking and Substance Involvement Screening Test (ASSIST) and urinalysis.
Results: Significant agreements between dichotomous and ASSIST scores were observed (K¼ 0.73–0.76). A higher rate
of self-reported (36.9%) alcohol use was detected, relative to urine screening (19.6%) with a predictive value of 34.9;
while underreporting of illicit substance use was observed (3.6% self-report vs. 8.8% urine screening) with an overall
predictive value of 50.0.
Conclusion: Dichotomous verbal screening was considered valid after comparison with the ASSIST; however, combined use
with urine screenings can be recommended especially for identifying illicit substance use in order to accurately detect alcohol
and other drug use in pregnancy, so that women can be identified and referred for appropriate interventions where needed.
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Introduction
Prenatal substance use (illicit drugs, alcohol, and
tobacco) is one of the largest modifiable risk factors
for significant gestational complications for both
women and their newborns.1–4 Polysubstance use
further increases the risk for adverse pregnancy out-
comes including miscarriage, low birth weight, preterm
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birth, stillbirth, and neurocognitive disorders.1–5
Maternal smoking, alcohol use, and drug use, each
increased the likelihood of having neonatal morbidity
including impaired Apgar scores (<7 at 5-min postpar-
tum), neonatal resuscitation, and neonatal intensive
care unit admission.6 While studies among certain pop-
ulations of pregnant women attending antenatal serv-
ices in the Western Cape have reported on rates of
substance use,7–9 to date, national prevalence of prena-
tal alcohol and other drug (AOD) use is not known in
South Africa, unlike in the U.S.10 However, locally, the
prevalence data of AOD use exist for overall
populations.11,12
Discrepancies between self-reported rate of AOD use
and biochemically verified use have been well docu-
mented, in which self-reported AOD use generally dem-
onstrated low sensitivity relative to biomarkers,13–15 in
part due to fear of judgment.16 Nevertheless, biochemical
screenings do not necessarily demonstrate clinical effica-
cy nor may they be ethically acceptable due to the legal
implications of prenatal substance use, at least in the U.
S.17 Although a severely punitive approach such as loss
of child custody does not happen in South Africa,18 fear
of exposure to stigmatization by healthcare providers
may increase under-reported AOD use among pregnant
women when asked in healthcare settings.19
A combined use of biochemical screenings with a stan-
dard self-report instrument (such as the Alcohol Smoking
and Substance Involvement Screening Test; ASSIST) is
encouraged for identifying substance use in pregnant
women;17 however, little international empirical evidence
supports this notion so far. For example, a previous
report of a cross-sectional survey at a community-based
prenatal clinic in South Africa showed that biochemical
screening (i.e. urinalysis) detected a higher prevalence of
prenatal drug use (8.8%) compared to the self-reported
dichotomous prevalence (3.6%), while the opposite trend
was found with prenatal alcohol use (i.e. 19.6% vs.
36.9%).8 Recent evidence with a large U.S. cohort of
pregnant women also showed that simple, dichotomous
self-report on prenatal substance, alcohol, and tobacco
use can still be useful to predict adverse birth outcomes
and start the conversation with obstetric providers on
substance use during pregnancy.20
The current study quantitatively explored the degree
of agreement among simple dichotomous self-report, val-
idated screening results, and biochemical screening
results in a South African cohort attending prenatal
care, in order to determine the level of validity with the
simple dichotomous self-report on prenatal AOD use.
Methods
The secondary analysis was based on a cohort of con-
senting pregnant women 16years or older, presenting to
community-based clinics called midwife obstetric units
(MOUs) in the greater Cape Town, a city in the
Western Cape region of South Africa. The procedure
of collecting demographic status and prenatal substance
and alcohol use has been stated elsewhere;8 however,
briefly, each participant received reimbursement for
their time and participation in the form of a chain store
voucher to the value of R50 (approximately $6). They
were also provided with a resource list. Ethical approval
to conduct the research was obtained from the Faculty of
Health Sciences Research Ethics Committee at the
University of Cape Town. Permission to conduct the
survey in the MOUs was obtained from the Western
Cape Department of Health.
Measures of substance use
Three means of assessing prenatal AOD use were com-
pared to determine the validity of simple dichotomous
self-report on prenatal substance use.
(1) Dichotomous self-report where women were
asked about alcohol or drug use during their current
pregnancy or in the three months before they knew
they were pregnant. These questions resemble current
standard care during intake, where pregnant women
are asked direct questions about current tobacco, alco-
hol, and drug use, (2) a validated assessment based on
the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST), and (3) urine screening.
The ASSIST is a brief screening questionnaire consist-
ing of eight items and was developed by the WHO and
an international team of substance use researchers as a
simple method of screening for hazardous, harmful and
dependent use of alcohol, tobacco, and other psychoac-
tive substances. The ASSIST was designed to screen for
substance abuse in primary care settings, and pregnant
women have been recommended as a target group suit-
able for an ASSIST screening program by the develop-
ers of this tool.21 A validity study conducted with 1047
subjects from seven countries, including Australia,
Brazil, India, Thailand, the UK, USA, and Zimbabwe,
showed that the ASSIST had good concurrent, con-
struct, predictive, and discriminative validity.22
Data analysis
Appropriate sampling weights were determined accord-
ing to the study design to generalize the results to the
described population of pregnant women. A survey
analysis was conducted, using appropriate weights for
the proportional allocation of women, to estimate the
reported drug and alcohol prevalence and 95% confi-
dence limits applied to the sample. A finite population
correction was also used.
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First, agreement between the self-reported substance
use using simple, dichotomous questions (yes/no), and
the substance use measured indirectly using the ASSIST
relating to the last three month’s substance use (aggregat-
ed responses; yes¼once or twice, monthly, weekly, daily;
no¼ never or not in the past threemonths) was measured
by the kappa statistic and 95% confidence interval.
The kappa values were calculated on the weighted
values in the 2 2 tables. To indicate the strength of
the agreement, the standards of Landis and Koch were
used: <0.00¼ poor; 0.00–0.20¼ slight; 0.21–0.40¼ fair;
0.41–0.60¼moderate; 0.61–0.80¼ substantial; and
0.81–1.00¼ almost perfect.23
Second, agreement between the responses to the
ASSIST and urinalysis results was examined, looking
at the sensitivity, specificity, positive predicted value
(PPV), and the negative predicted value (NPV) with
95% confidence intervals were reported as measures
of validity. The analyses were undertaken for cannabis,
heroin, methamphetamine, and benzodiazepine as well
as for all drugs combined. For the urinalysis, the stan-
dardized cut-off values for the individual drugs were
used to indicate positive use of the specific drug. The
observed frequency tables were reported and thereafter
the 2 2 tables. The measures of validity were calcu-
lated for the weighted values in the 2 2 tables.
Analyses were conducted using SAS version 9.4.
Results
Characteristics of the sample
In total, 5231 pregnant women screened for AOD use
during their current pregnancy and/or in the three
months before they knew they were pregnant. Of
these, 684 (13.1%) were intentionally sub-sampled
and completed ASSIST screening and provided a
urine sample for biological screening. Self-reported
alcohol and drug use were compared with urine
screens. The 684 participants had a mean age of
26 years (SE¼ 0.25); 60.3% were Black African,
39.1% coloured (of mixed-race ancestry), and 1.6%
White or Asian. Ninety-two percent had some second-
ary education, 66.9% were never married/single, and
56.9% unemployed. The majority of participants had
five or more of the listed assets in their homes (75.9%)
indicating higher socio-economic status compared to
those with four or less items. Approximately two-
thirds were multiparous. Over half the participants
reported that their current pregnancy was unplanned
(68.2%), and the mean gestational age at the booking
visit was 18.9weeks with the majority of women book-
ing in their second trimester (57.4%) (Table 1).
Prevalence of AOD use
An estimation of the prevalence of substance use was
conducted, taking into account stratified proportional
allocation, adjusting variance for stratified proportion-
al sampling. Three assessments of drug use were used
to estimate prevalence: dichotomous self-report in the
screened sample (N¼ 5231); an assessment based on
the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST) (N¼ 684); and biological
urine tests (N¼ 592). Ninety-five urine samples were
not tested for any (n¼ 34) or some (n¼ 61) substances

















Legally married 18.9 1.65
Traditionally married 7.7 1.15
Living together 4.1 0.84




Employed full-time 23.7 1.86
Employed part-time/self-employed 12.0 1.43
Student 7.4 1.10
Socio-economic status
Low (four or less items) 24.1 1.78











0–12 weeks (first trimester) 22.8 1.90
13–24 weeks (second trimester) 57.4 2.30
25–40 weeks (third trimester) 19.8 1.80
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because of a fault of the testing laboratory, which
accounted for 12.2% of the total samples.
Dichotomous self-report (N¼ 5231) showed that
3.6% (95% CI: 3.1–4.0) reported at least one illicit
substance use and 36.9% (95% CI: 35.6–38.1) reported
alcohol use. ASSIST screening (N¼ 684) showed that
4.7% reported at least one illicit substance use and
36.8% reported alcohol use. Urinalyses (N¼ 592)
showed that 8.8% (95% CI: 6.7–10.9) tested positive
for at least one illicit substance and 19.6% (95% CI:
16.3–22.8) tested positive for alcohol use.
Agreement between dichotomous
and ASSIST screenings
The overall measure of agreement between the dichot-
omous self-reported AOD rate and AOD rate screened
by ASSIST was statistically significant (K¼ 0.76; 95%
CI 0.71–0.81 and K¼ 0.73; 95% CI 0.59–0.86 for alco-
hol and drug use, respectively), indicating a strong
agreement between the two means of verbal screenings.
Agreement between dichotomous and urinalyses
Urinalyses showed the rate of illicit substance use that
was higher than dichotomous self-report (3.6% vs.
8.8%), and the rate of alcohol use that was lower
than dichotomous self-report (36.9% vs. 19.6%).
Agreement between ASSIST and urine screenings
Table 2 shows agreements between ASSIST and urine
screening with respect to sensitivity, specificity, and
predictability. The weighted sensitivity (the proportion
of self-reports of alcohol use among those testing pos-
itive for alcohol use) of self-report for alcohol use using
the ASSIST as compared to biomarkers was 58.5%
(CI: 48.9–68.1), and the weighted specificity (the pro-
portion of self-reports of no alcohol use among those
testing negative for alcohol use) was 68.7% (CI: 63.9–
73.6). The positive predictive value, which indicates
how likely someone with a positive test result is to
actually have the characteristic or be a user of alcohol,
was 34.9%.
The weighted sensitivity of self-report for other drug
use was 22.5%, and the specificity was 97.5%. The PPV
was 50.0%. The weighted sensitivity for self-report of
Cannabis use compared to biomarkers was 51.4%
(95% CI: 27.8–74.9), and the specificity was 98.4%
(95% CI: 97.7–99.2) with the PPV of 37.6%.
Sensitivity analysis was not conducted for heroin use
due to the small sample size (n¼ 5) with specificity of
99.9%. The weighted sensitivity of self-report of meth-
amphetamine was 13.3%, and the specificity was
98.5% with the PPV of 46.8%. No participant reported
benzodiazepine use (Table 2).
Discussion
The current study showed that simple, dichotomous
self-report showed a good agreement with ASSIST
verbal screening. This indicates that simple, dichoto-
mous self-report is a reliable means of detecting prena-
tal AOD use among pregnant women in the Western
Cape region of South Africa. However, ASSIST iden-
tified more alcohol use and less illicit drug use com-
pared to urine screenings. This indicates that
pregnant women in the Western Cape region of
South Africa are willing to disclose alcohol use, but
tend to underreport drug use.
Data from studies conducted in the USA show that
pregnant women are more likely to underreport alcohol
use during pregnancy for the concern of stigmatiza-
tion.16 Although public health messaging regarding
harmful effects of drinking during pregnancy is avail-
able, and a brief intervention to educate pregnant
mothers has been effective with a South African
cohort,24 socioeconomically disadvantaged pregnant
women enter late in prenatal care as found in this
study. The reasons for this are complex and vary but
includes importantly women’s perceptions of quality of
care, which influences their health seeking practices.25
It should be noted that underreporting of prenatal
alcohol use might increase as the norm around per-
ceived harm of prenatal alcohol use changes.
Contrary to reporting alcohol use, report of illicit
substance use or noncompliance with a treatment plan
Table 2. Sensitivity, specificity, positive predictive value, and negative predictive value between ASSIST and urine screenings for





specificity 95% CI PPV 95% CI NPV 95% CI
Alcohol 58.5 48.9–68.1 68.7 63.9–73.6 34.9 27.5–42.2 85.3 81.5–89.0
Cannabis 51.4 27.8–74.9 98.4 97.7–99.2 37.6 21.0–54.1 99.1 98.4–99.8
Heroin NA – 99.9 99.9–100.0 – – – –
Methamphetamine 13.3 8.5–18.1 98.5 97.5–99.5 46.8 29.9–63.8 91.8 89.3–94.2
Benzodiazepine NA – 99.9 99.7–99.9 – – – –
Drugs overall 22.5 15.2–29.9 97.5 96.3–98.7 50.0 36.0–64.0 91.9 89.4–94.3
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among mothers can result in rather severe legal conse-
quences such as loss of child custody and incarceration
in the U.S.17 This is not the case with South Africa to
date,18 and potential consequence of reported illicit drug
use is assignment of case management by a social
worker; however, stigmatization by healthcare profes-
sionals on prenatal illicit drug use19 is potentially the
reason of underreported drug use in the current study.
Due to low disclosure rate of drug use among pregnant
women, the combined verbal and urine screenings are
recommended to determine the national prevalence of
prenatal drug use; while, verbal screening only captures
the prevalence of prenatal alcohol use. However, ques-
tions around the affordability of this remain and the
availability of resources to respond appropriately.
A few limitations are noted in the current study. Not
all pregnant patients volunteered for the study; there-
fore, this was considered a convenient sample. Not all
participants who were screened with ASSIST had their
urines tested due to laboratory issues with some sam-
ples being inadvertently destroyed.
The current study contributes to the existing literature
in the following ways: (1) ASSIST verbal screening dem-
onstrated a high agreement with dichotomous verbal
screening with a South African cohort which implies
that we can continue using simple questioning about use
(yes/no); (2) the rate of self-reported prenatal alcohol use
was higher than that of urine screening with the cohort,
contrary to the U.S.; (3) the rate of self-reported illicit
drug use was lower than that of urine screening with the
cohort, consistent with the literature in the U.S.
In summary, the current study examined agreements
between dichotomous verbal screening, validated
verbal screening, and urine screening in prenatal
AOD use with a South African cohort. High rate of
self-reported prenatal alcohol use was observed; how-
ever, illicit drug use was underreported. Dichotomous
verbal screening was considered valid after comparison
with the validated verbal screening method; however,
combined use with urine screenings can be recom-
mended especially for identifying underreported sub-
stances in order to accurately detect AOD use in
pregnancy, so that women can be identified and
referred for appropriate interventions where needed.
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